[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-reported-outcome-pro\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-reported-outcome-pro":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,51,85,119,142,173,203,243,271],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100649625","examining-relationships-between-musculoskeletal-function-measurements-of-movement-efficiency-and-nervous-system-function-after-chronic-stroke-100649625",false,"NCT07737873","Examining Relationships Between Musculoskeletal Function Measurements of Movement Efficiency and Nervous System Function After Chronic Stroke","SOMADC-CC (SOMAtic Dysfunction Characterization Following Chronic Cerebrovascular Disease): Biomarker Study","SOMADC-CC","Inclusion Criteria:\n\n* • UC Davis Stroke Clinic outpatient patients \\>3 months from previous stroke\n\n  * Adults ≥18 years\n  * Previous admission diagnosis or referral indication:\n\n    o Ischemic stroke (prior history of)\n  * Able to sit upright, lie supine, and lie lateral recumbent left\u002Fright positions\n  * Must be able to walk independently with\u002Fwithout walking aids.\n  * Participants must have the capacity to consent to study participation themselves or have a Legally Authorized Representative (LAR) available.\n  * Willingness to receive SMS (text) messages and\u002For email to complete REDCap QoL survey\n\nExclusion Criteria:\n\n* • Acute skeletal fracture or known dislocation; history of pathologic (osteoporotic or neoplastic) skeletal fracture of thoracic cage, hip\u002Fpelvis\u002Fsacrum, or vertebral column\n\n  * Spinal column support brace (e.g. cervical collar)\n  * History of spinal cord injury with residual neuromuscular or sensory disability\n  * Clinical condition that would interfere with execution of movement or palpatory diagnostic testing, e.g. prohibitive chronic pain\n  * Participants who have received either OMT or chiropractic manipulation following their stroke and prior to enrollment.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","1 Day","OBSERVATIONAL","Stroke remains the leading cause of severe disability, and survivors frequently have incomplete recovery. More than half of older survivors have impaired mobility which contributes to poorer quality-of-life (QoL) and suffering. The annual rate of disability compared to myocardial infarction triples, and stroke accelerates natural age-related functional decline. Somatic dysfunction (SD) is impaired function of the body framework identified by physical examination. Few studies have rigorously studied SD among stroke survivors. We recently demonstrated the reliability of a novel, more construct valid osteopathic examination methodology \\[called the Functional Pathology of the Musculoskeletal System (FPMSS) model\\] to quantify SD among asymptomatic participants and patients with acute cerebral ischemia. The preliminary findings suggest that dysfunction may develop within the first week after acute ischemic stroke (IS) and be more severe among those with paralysis compared to healthy volunteers. The precise pathophysiologic mechanism underlying SD remains unknown.\n\nThe objective of this proposal is to establish the relationship between SD severity during chronic stroke recovery and physiologic biomarkers. The central hypothesis is that SD is quantifiable, correlates with biomarkers that reflect functional status, and is associated with QoL among chronic stroke survivors. There are currently no biomarkers that correlate with SD severity after IS. Establishing valid biomarkers associated with physiologic processes that are otherwise inferred by physical examination would allow for quantification of changes in response to treatment (e.g., osteopathic manipulative treatment; OMT) aimed at restoring economical biomechanical function. Testing this hypothesis will address several fundamental gaps in knowledge about osteopathic palpatory diagnosis, physiologic processes associated with SD, and its association with survivor outcomes. Until these knowledge gaps are filled, optimal strategies to complement stroke recovery in patients with neurological disability cannot fully be determined. The project specific aims are to quantify the association between SD among chronic (\\>3 months) IS survivors and measured (1) energy expenditure, (2) heart rate variability (HRV), and (3) patient-reported outcome (PRO) health domains.\n\nThe proposed research is significant because it will establish a novel osteopathic approach that determines the impact of whole musculoskeletal system (MSS) health on QoL among stroke survivors living with chronic disability and correlate physiologic properties related to SD. This approach will allow us to quantify SD and show meaningful associations with autonomic function, biomechanical economy, and QoL after chronic stroke. These new metrics would then be derived in stroke patients to determine SD and physiologic thresholds for those that would benefit most from OMT in a future trial. This proposal is innovative in that it seeks to shift current research and practice paradigms by re-appraising the impact of whole musculoskeletal functional economy on patient-centered outcomes among stroke survivors. Methodologically, use of the FPMSS model represents a novel, more construct valid, diagnostic paradigm to reliably identify SD and establish an osteopathic, cross-disciplinary approach to the field of stroke research. The model examines the MSS as integrated, highlighting proportionate, not merely symmetrical, posture and motion among survivors with chronic disability. Similarly, PROs have been used to quantify health status after stroke, but have not been used to study the relationship between chronic neurologic impairment and SD. Integrating contemporary patient-centered stroke outcomes, rigorous osteopathic assessment, and analysis of physiologic processes will advance our understanding of how musculoskeletal dysfunction impacts QoL after stroke.",[26,27,28,29,30,31],"Stroke","Osteopathic Medicine","Physical Examination","Heart Rate Variability (HRV)","Energy Expenditure","Patient Reported Outcome (PRO)",[33,34,35,36,37],"stroke","osteopathic medicine","patient reported outcome","heart rate variability","physical examination","RECRUITING","2026-07-27",{"date":41,"type":42},"2026-07-30","ACTUAL",{"date":44,"type":21},"2026-07-01",{"date":46,"type":21},"2028-06-30",{"name":48,"class":49},"University of California, Davis","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":50},"100647257","preoperative-anxiety-and-one-year-patient-reported-outcomes-in-orthopedic-surgery-patients-receiving-enhanced-recovery-after-surgery-or-conventional-care-100647257","NCT07706244","Preoperative Anxiety and One-year Patient-reported Outcomes in Orthopedic Surgery Patients Receiving Enhanced Recovery After Surgery or Conventional Care","A Prospective Cohort Study Comparing Preoperative Anxiety and One-Year Patient-Reported Outcomes Between Enhanced Recovery After Surgery and Conventional Care in Orthopedic Surgery Patients","ERAS-APO","Inclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Age \\>= 20 years.\n  2. Hospitalized patients scheduled for elective major orthopedic surgery (such as total knee arthroplasty, total hip arthroplasty, or spinal surgery).\n  3. Possess sufficient language comprehension and expression skills to complete interviews and questionnaires in Mandarin, Taiwanese, Hakka, or English.\n  4. Agree to participate in the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Patients requiring immediate management due to emergency or traumatic urgent surgery.\n2. Diagnosed by a physician with significant cognitive impairment, delirium, or severe mental illness resulting in the inability to complete evaluation and follow-up.\n3. Severe and unstable medical conditions (such as ASA-V, shock, or requiring long-term intensive care treatment).\n4. Anticipated requirement for intensive care unit (ICU) admission postoperatively.\n5. Concurrent participation in other clinical trials or intervention studies that would affect anxiety or functional outcomes.\n6. Patients for whom follow-up up to 12 months is inconvenient or difficult during the study period.","20 Years","100 Years",{"count":62,"type":21},220,"This study investigates whether an Enhanced Recovery After Surgery (ERAS) program can help orthopedic surgery patients feel less anxious before their operation and recover better one year after surgery, compared to conventional (standard) surgical care.\n\nPatients who undergo orthopedic surgery, such as joint replacement, often experience significant anxiety before the operation. While ERAS programs, which combine patient education, pain management, and early mobilization, have been shown to shorten hospital stays and reduce complications, less is known about whether they also reduce preoperative anxiety and lead to better long-term outcomes reported by patients themselves.\n\nIn this prospective cohort study, patients receiving ERAS care will be compared with patients receiving conventional care. Preoperative anxiety will be measured using a validated questionnaire (APAIS). Clinical recovery during hospitalization, including length of stay, pain scores, and opioid use, will also be recorded. Patients will then be followed for one year to assess their quality of life (EQ-5D-5L) and their own impression of overall improvement (Patient Global Impression of Change).\n\nThe goal of this study is to determine whether ERAS not only improves short-term surgical recovery, but also reduces preoperative anxiety and leads to better long-term, patient-centered outcomes.",[65,66,31],"Preoperative Anxiety","Orthopedic Surgery",[68,69,70,71,72,73,74,75],"Enhanced Recovery After Surgery","ERAS","APAIS","EQ-5D-5L","Patient Global Impression of Change","Quality of Life","Cohort Study","Perioperative Care","2026-07-16",{"date":78,"type":42},"2026-07-17",{"date":80,"type":42},"2025-11-01",{"date":82,"type":21},"2027-12",{"name":84,"class":49},"Buddhist Tzu Chi General Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":50},"100643615","digital-support-for-multiple-myeloma-quality-of-life-100643615","NCT07642362","Digital Support for Multiple Myeloma Quality of Life","Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)","DigiMyQoL","Inclusion Criteria:\n\n* Adult patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients that are able to use the digital platform\u002Fapplication\n\nExclusion Criteria:\n\n* Patients that are not able to use the digital platform\u002Fapplication",{"count":94,"type":21},108,"INTERVENTIONAL",[97],"NA","The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.\n\nSpecifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.",[100,31,101,73],"Multiple Myeloma","Supportive Care in Cancer",[103,104,105,35,106,107,108],"multiple myeloma","quality of life","qol","pro","digital oncology","supportive care","2026-06-07",{"date":111,"type":42},"2026-06-11",{"date":113,"type":42},"2025-02-27",{"date":115,"type":21},"2028-03",{"name":117,"class":118},"CareAcross","INDUSTRY",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":50},"100631808","screening-for-supportive-care-needs-of-oncological-patients-and-professionals---evaluation-of-a-short-pro-question-set-100631808","NCT07505498","Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO: Screening for Supportive Care Needs of Oncological Patients and Professionals - Evaluation of a Short PRO-question Set","Scope-PRO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Capacity to give consent\n* Cancer patients\n* Sufficient understanding of the German language\n\nExclusion Criteria:\n\n* Minors\n* Lack of capacity to give consent\n* Insufficient knowledge of German",{"count":128,"type":21},900,"The systematic recording of patient-reported symptoms and health-related quality of life (patient-reported outcomes, PROs) is a central component of oncological care. Currently, however, screening for support needs in German hospitals is inconsistent and uses different assessment tools, leading to heterogeneity, redundant surveys, and limited comparability of results. This complicates standardized, patient-centered, and cross-sector care, as well as the early identification of therapy-associated side effects and support needs.\n\nThe aim of the study is to investigate the acceptance and relevance of the core set of questions from the perspective of both cancer patients and professional healthcare providers. Cancer patient acceptance will be measured by the proportion of fully completed questionnaires, while cancer patient relevance will be assessed using a feedback form. The professional perspective will be gathered through guided feedback in quality circles conducted regularly in accordance with internal standards",[131,132,31],"Patient Related Outcome Measures","Supportive Care","2026-03-29",{"date":135,"type":42},"2026-04-01",{"date":137,"type":42},"2025-12-01",{"date":139,"type":21},"2027-12-31",{"name":141,"class":49},"University Medical Center Goettingen",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":95,"phases":151,"briefSummary":152,"conditions":153,"keywords":160,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":50},"100629062","multidisciplinary-care-pathway-tailored-on-frailty-in-cancer-patients-referred-to-outpatient-palliative-care-100629062","NCT07469761","MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care","MISTRAL","Inclusion Criteria:\n\n* diagnosis of advanced\u002Fmetastatic cancer\n* age \\> 18\n* Eastern Cooperative Oncology Group (ECOG) performance status ≥2\n* prognostic clinical prediction \\>1 month.\n\nExclusion Criteria:\n\n* Serious medical or psychiatric illness that can interfere with informed consent and participation in this clinical study\n* any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.",{"count":150,"type":21},120,[97],"The goal of this clinical trial is to learn whether a structured, Patient-Reported Outcome Measures (PROMs)-tailored palliative care pathway improves clinical outcomes and care experience in adults with advanced cancer referred to outpatient palliative care.\n\nPatients with advanced cancer often experience multiple symptoms and complex needs. Standard outpatient palliative care is usually guided by clinical judgment on patient-reported questionnaires. In this study, researchers aim to test whether a more structured approach, based on predefined cut-offs from PROMs, can improve symptom control, satisfaction with care, and use of healthcare resources. The main questions the study aims to answer are:\n\nDoes a structured, PROM-driven palliative care pathway reduce symptom burden and psychological distress compared with usual care? And through this, to improve patients' and caregivers' satisfaction with care or reduce emergency room visits, hospital admissions, healthcare costs, and aggressive treatments near the end of life?\n\nResearchers will compare two groups:\n\nControl group: Participants will receive standard outpatient palliative care. PROMs are collected as usual, but without predefined cut-offs or structured intervention checklists.\n\nExperimental group: Participants will receive a structured palliative care pathway tailored to symptoms\u002Fneeds identified at baseline using PROM cut-offs. Specific multidisciplinary interventions are activated according to identified needs.",[154,155,31,156,157,158,159],"Palliative Care","Palliative Care, Health Services","Patient Reported Outcome Measurements","Frailty","Cancer","Outpatient",[161,159,154,162,157,163],"Patient Reported Outcome Measurements (PROMs)","Advanced cancer","Palliative Care intervention","2026-03-09",{"date":166,"type":42},"2026-03-13",{"date":168,"type":42},"2025-11-02",{"date":170,"type":21},"2027-02-28",{"name":172,"class":49},"Augusto Caraceni",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100615167","patient-reported-outcomes-in-allogeneic-stem-cell-transplantation-and-car-t-therapy-100615167","NCT07289087","Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy","A Real-World Observational Study on Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation (Allo-SCT) and CAR-T Therapy","QOL-ONE PRO-CT","Inclusion Criteria:\n\n* Diagnosed with a hematologic malignancy (e.g., leukemia, lymphoma, multiple myeloma)\n* Undergoing either allogeneic SCT or CAR-T therapy\n* Able and willing to provide written informed consent\n* Sufficient Italian proficiency to complete the HM-PRO\n* Signed informed consent\n\nExclusion Criteria:\n\n* Cognitive or physical impairments that preclude the ability to complete questionnaires\n* Estimated life expectancy \\\u003C 7 days at the time of admission",{"count":182,"type":21},162,"3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients receiving CAR-T cell therapy. Patients will be enrolled at hospital admission for the index inpatient procedure and followed through the inpatient stay (admission → discharge). The study is non-randomized and designed to describe trajectories of symptoms and HRQoL and to estimate the between-group difference in deterioration of HM-PRO scores (primary estimand: mean difference in change score, CAR-T vs allo-SCT).",[73,31,185,186],"Allogeneic Blood and Marrow Transplantation (BMT)","CAR T Cell Therapy",[73,188,189,190,191,100,192],"CAR-T cell therapy","Allogenic BMT","Patient Reported Outcome","Leukemia","Lymphoma","NOT_YET_RECRUITING","2025-12-04",{"date":196,"type":42},"2025-12-17",{"date":198,"type":21},"2026-02-15",{"date":200,"type":21},"2027-04-01",{"name":202,"class":49},"Associazione Qol-one",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":95,"phases":213,"briefSummary":214,"conditions":215,"keywords":225,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":50},"100566450","efficiency-of-the-medidux-smartphone-app-for-demission-management-in-patients-medicated-in-acute-admission-unit-aau-100566450","NCT06655337","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)","Efficiency of the \"Medidux\" Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU): a Randomized Controlled Trial.","EffiDux","Inclusion Criteria:\n\n* Signed Informed Consent Form (ICF)\n* Age ≥ 18 years\n* (Self-)admission to the involved Acute Admissions Unit (AAU)\n* \"Lead symptom\" identified as coughing, back pain or abdominal discomfort\n* Participant within ESI triage system group 4 (standard) and 5 (non-urgent)\n* German-speaking\n* Ownership of a smartphone or other mobile device with iOS or Android operating system\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Participant whose compliance to the study's protocol, e.g. due to mental health problems, physical problems, or the private life situation, can be justifiably doubted\n* Participant with insufficient knowledge about the use of a smartphone or other mobile device with iOS or Android operating system\n* Participant already using or planning to use another comparable electronic patient-reported symptom monitoring system (e.g. CANKADO) during this trial",{"count":212,"type":21},417,[97],"The goal of this clinical trial is to evaluate whether the use of the medidux™ smartphone app can optimize post-discharge management for patients admitted to Acute Admission Units (AAU) with non-urgent health complaints. This trial includes adult patients (age ≥ 18) in Emergency Severity Index (ESI) triage system groups 4 (standard) or 5 (non-urgent), presenting with primary symptoms such as cough, back pain, or abdominal discomfort.\n\nThe main question it aims to answer is:\n\nCan the medidux™ app reduce the incidence of AAU readmissions, emergency hospitalizations, or consultations with other medical providers within 7 days after initial admission?\n\nResearchers will compare participants using the medidux™ app (intervention arm) with those receiving standard care (control arm) to observe potential differences in the rates of readmissions, emergency hospitalizations, and medical consultations.\n\nParticipants will:\n\n* use the medidux™ app to monitor their symptoms and vital parameters for 7 days after discharge (intervention arm).\n* receive follow-up consultations at day 7 and at day 28 to assess symptom progression and any healthcare interactions (both arms).",[216,217,218,219,220,221,222,223,224,31],"Acute Disease","Acute Hospitalization","Coughing","Back Pain","Abdominal Pain (AP)","Patient Discharge","Patient Readmission","Mobile Health Apps","Mobile Health Technology (mHealth)",[216,221,222,218,219,226,227,228,229,230,231,232,233],"Abdominal Pain","Mobile Health Applications","Remote Monitoring","Post-discharge Care","Symptom Monitoring","Health Behaviour","Telemedicine","Randomized Controlled Trial","2025-09-29",{"date":236,"type":42},"2025-10-03",{"date":238,"type":42},"2025-09-28",{"date":240,"type":21},"2027-03-28",{"name":242,"class":118},"Mobile Health AG",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":249,"sex":17,"minAge":250,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":253,"conditions":254,"keywords":258,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":50},"100600180","clinical-and-radiographic-outcomes-of-the-jointmedica-custom-made-resurfacing-device-100600180","NCT07094139","Clinical and Radiographic Outcomes of the JointMedica Custom-Made Resurfacing Device","Inclusion Criteria:\n\n* Age 21 or above at the time of the surgery.\n* Have had the JointMedica Custom-Made Hip Resurfacing device implanted between September 2020 to January 2025\n* Written informed consent given by subject\n\nExclusion Criteria:\n\n* There is no exclusion criteria for this study",true,"21 Years",{"count":252,"type":21},41,"The Custom Resurfacing (CR) Implants are indicated for use for the reduction or relief of pain and\u002For improved hip function all skeletally mature patients where a total joint replacement is indicated, and where there is no other suitable, commercially distributed device available.\n\nThe Resurfacing System is a metal-on-polyethylene hip resurfacing device consisting of a metallic femoral component and an acetabular component made of Vitamin E HXLPE with a titanium coating on its bone-contacting surface.\n\nThe custom-Made Hip Resurfacing System is a single use device intended for hybrid fixation: cemented femoral head component and cementless acetabular component.\n\nThe goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the treatment of hip osteoarthritis.\n\nThis study will assess the following endpoints:\n\n* The survivorship of the Acetabular Cup (Kaplan-Meier estimate) through 2 years of follow-up.\n* Radiographic success of the implanted cups, through quantitative motion analysis to assess migration of the acetabular cups.\n* Absence of subsequent surgical intervention at the acetabulum of there operated hip.\n* Absence of serious, device-related adverse events.\n* Patient reported outcomes through Harris Hip Score and SUSHI - UCLA Hip Score questionnaires.",[255,256,257,31],"Healthy","Real World Data","Safety and Effectiveness",[259,260,261],"Custom-Made Hip Resurfacing","Hip Resurfacing","Hip Arthroplasty","2025-07-23",{"date":264,"type":42},"2025-07-30",{"date":266,"type":21},"2025-08",{"date":268,"type":21},"2026-12",{"name":270,"class":49},"JointMedica Inc.",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":249,"sex":17,"minAge":250,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":279,"conditions":280,"keywords":281,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100599144","clinical-and-radiographic-outcomes-of-the-jointmedica-polymotion-resurfacing-phr-device-100599144","NCT07080671","Clinical and Radiographic Outcomes of the JointMedica Polymotion Resurfacing (PHR) Device","Inclusion Criteria:\n\n* Age 21 or above at the time of the surgery.\n* Have had the Polymotion Hip Resurfacing (PHR) (implanted between September 2020 to January 2025\n* Written informed consent given by subject\n\nExclusion Criteria:\n\n* There is no exclusion criteria for this study",{"count":278,"type":21},105,"The goal of this observational study is to generate Real World Evidence (RWE) on the device performance of the Polymotion Hip Resurfacing (PHR) system and its use in patients who have been implanted with the device for the treatment of hip osteoarthritis.\n\nThis study will assess the following endpoints:\n\n* The survivorship of the Acetabular Cup (Kaplan-Meier estimate) through 2 years of follow-up.\n* Radiographic success of the implanted cups, through quantitative motion analysis to assess migration of the acetabular cups.\n* Absence of subsequent surgical intervention at the acetabulum of there operated hip.\n* Absence of serious, device-related adverse events.\n* Patient reported outcomes through Harris Hip Score and SUSHI - UCLA Hip Score questionnaires.",[255,256,257,31],[282,283,284],"PHR","Polymotion Hip Resurfacing","Polymotion","2025-07-15",{"date":262,"type":42},{"date":288,"type":21},"2025-07-25",{"date":290,"type":21},"2026-12-31",{"name":270,"class":49},3]